RedHill Reports FY Earnings: Revenue and Cash Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy RDHL?
Source: seekingalpha
- Earnings Overview: RedHill's FY report indicates a GAAP EPS of $0.00, reflecting a lack of profitability that may dampen investor confidence in the company's financial health.
- Revenue Figures: The reported revenue stands at $0.29 million, which, while indicating some income, falls short of industry benchmarks, potentially limiting future growth prospects.
- Cash Position: As of December 31, 2025, RedHill's cash balance is $4.1 million, maintaining a degree of liquidity; however, this may restrict the company's ability to invest in R&D and market expansion.
- Future Outlook: Given the current financial situation, RedHill must develop effective strategies to enhance revenue and profitability to navigate market competition and attract greater investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDHL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDHL
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RedHill's RHB-204 Shows Promising Phase 2 Results for Crohn's Disease
- Clinical Trial Success: RHB-104 demonstrated a 64% improvement in efficacy in its Phase 3 study, achieving the primary endpoint of clinical remission, indicating a significant advantage in treating Crohn's disease and potentially transforming current treatment paradigms.
- New Drug Development Progress: In vitro testing of RHB-204 showed comparable Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy to RHB-104, but with lower doses of active ingredients, suggesting reduced toxicity and side effects, thereby enhancing patient adherence.
- Significant Market Opportunity: The Crohn's disease market is projected to grow from $13.6 billion in 2024 to over $19 billion by 2033, with FDA approval of RHB-204 potentially providing substantial market share and revenue opportunities for the company.
- Clear Regulatory Pathway: RHB-204 is expected to receive FDA pediatric orphan drug designation and breakthrough therapy designation, further enhancing its competitive edge and regulatory advantages, which are anticipated to yield long-term strategic benefits for the company.
See More
RedHill Reports FY Earnings: Revenue and Cash Position
- Earnings Overview: RedHill's FY report indicates a GAAP EPS of $0.00, reflecting a lack of profitability that may dampen investor confidence in the company's financial health.
- Revenue Figures: The reported revenue stands at $0.29 million, which, while indicating some income, falls short of industry benchmarks, potentially limiting future growth prospects.
- Cash Position: As of December 31, 2025, RedHill's cash balance is $4.1 million, maintaining a degree of liquidity; however, this may restrict the company's ability to invest in R&D and market expansion.
- Future Outlook: Given the current financial situation, RedHill must develop effective strategies to enhance revenue and profitability to navigate market competition and attract greater investor interest.
See More
Emerging Trends in H. pylori Infection Market
- Market Size Growth: The H. pylori infection market is projected to reach $270 million by 2025, with the U.S. accounting for 85% of this market, indicating strong demand for new therapies and significant future market potential.
- Emerging Therapy Development: New therapies like Rifasutenizol from TenNor Therapeutics show over 90% eradication rates in clinical trials, potentially becoming the first innovative therapy for H. pylori, enhancing treatment efficacy and reducing resistance risks.
- Optimized Treatment Strategies: The incorporation of bismuth into triple therapy has increased eradication rates by 30-40%, reflecting effective strategies against antibiotic-resistant H. pylori and driving improvements in treatment standards.
- Adult-Pediatric Treatment Differences: Adult guidelines emphasize widespread eradication to lower gastric cancer risks, while pediatric recommendations require more cautious, targeted strategies, creating opportunities for personalized prevention and intervention programs.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Talicia Full Sales Launch Begins, Unlocking Market Potential
- Accelerated Market Penetration: The full sales launch of Talicia under the joint commercialization agreement between RedHill and Cumberland aims to enhance market penetration, potentially increasing Talicia's market share in the U.S. to meet the treatment needs of approximately 1.6 million patients annually.
- Unique Treatment Solution: Talicia is the only FDA-approved low-dose rifabutin-based therapy for H. pylori, addressing antibiotic resistance, and is recommended as a first-line treatment in the 2024 ACG Clinical Guidelines, which is expected to drive prescription growth significantly.
- Strategic Investment Support: Cumberland's $4 million investment in this initiative supports the marketing and operational efforts for Talicia, enhancing the collaboration between the two companies in the gastrointestinal disease sector and improving overall commercialization capabilities.
- Global Market Expansion: RedHill is actively exploring new market opportunities for Talicia in the UK and the Middle East, aiming to broaden market access and secure additional non-dilutive revenue streams, thereby increasing treatment accessibility for patients worldwide.
See More
RedHill Biopharma's RHB-102 Progress Drives 36% Rally, Stock Drops 4.29%
- Stock Volatility: RedHill Biopharma's stock fell 4.29% to $1.34 on Tuesday after a 36% rally on Monday, indicating potential profit-taking that may affect investor confidence in the short term.
- Development Progress: The company announced advancements for RHB-102 (Bekinda) in multiple gastrointestinal indications, utilizing the FDA's accelerated 505(b)(2) pathway, which aims to address GI side effects associated with GLP-1/GIP receptor agonist therapies, presenting significant market potential.
- Clinical Data Support: Clinical data for RHB-102 comes from the U.S. Phase 3 GUARD gastroenteritis study and the positive Phase 2 IBS-D study, both meeting their primary endpoints, which are expected to provide strong support for FDA approval and potentially reshape the GLP-1 market landscape.
- Market Impact: With up to 50% of patients discontinuing GLP-1 receptor agonists within three months due to side effects, successful development of RedHill's therapy could mitigate the projected $35 billion reduction in GLP-1 market valuations by 2030.
See More
RedHill's RHB-204 Shows Promising Phase 2 Results for Crohn's Disease
- Clinical Trial Success: RHB-104 demonstrated a 64% improvement in efficacy in its Phase 3 study, achieving the primary endpoint of clinical remission, indicating a significant advantage in treating Crohn's disease and potentially transforming current treatment paradigms.
- New Drug Development Progress: In vitro testing of RHB-204 showed comparable Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy to RHB-104, but with lower doses of active ingredients, suggesting reduced toxicity and side effects, thereby enhancing patient adherence.
- Significant Market Opportunity: The Crohn's disease market is projected to grow from $13.6 billion in 2024 to over $19 billion by 2033, with FDA approval of RHB-204 potentially providing substantial market share and revenue opportunities for the company.
- Clear Regulatory Pathway: RHB-204 is expected to receive FDA pediatric orphan drug designation and breakthrough therapy designation, further enhancing its competitive edge and regulatory advantages, which are anticipated to yield long-term strategic benefits for the company.
See More
RedHill Reports FY Earnings: Revenue and Cash Position
- Earnings Overview: RedHill's FY report indicates a GAAP EPS of $0.00, reflecting a lack of profitability that may dampen investor confidence in the company's financial health.
- Revenue Figures: The reported revenue stands at $0.29 million, which, while indicating some income, falls short of industry benchmarks, potentially limiting future growth prospects.
- Cash Position: As of December 31, 2025, RedHill's cash balance is $4.1 million, maintaining a degree of liquidity; however, this may restrict the company's ability to invest in R&D and market expansion.
- Future Outlook: Given the current financial situation, RedHill must develop effective strategies to enhance revenue and profitability to navigate market competition and attract greater investor interest.
See More
Emerging Trends in H. pylori Infection Market
- Market Size Growth: The H. pylori infection market is projected to reach $270 million by 2025, with the U.S. accounting for 85% of this market, indicating strong demand for new therapies and significant future market potential.
- Emerging Therapy Development: New therapies like Rifasutenizol from TenNor Therapeutics show over 90% eradication rates in clinical trials, potentially becoming the first innovative therapy for H. pylori, enhancing treatment efficacy and reducing resistance risks.
- Optimized Treatment Strategies: The incorporation of bismuth into triple therapy has increased eradication rates by 30-40%, reflecting effective strategies against antibiotic-resistant H. pylori and driving improvements in treatment standards.
- Adult-Pediatric Treatment Differences: Adult guidelines emphasize widespread eradication to lower gastric cancer risks, while pediatric recommendations require more cautious, targeted strategies, creating opportunities for personalized prevention and intervention programs.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Talicia Full Sales Launch Begins, Unlocking Market Potential
- Accelerated Market Penetration: The full sales launch of Talicia under the joint commercialization agreement between RedHill and Cumberland aims to enhance market penetration, potentially increasing Talicia's market share in the U.S. to meet the treatment needs of approximately 1.6 million patients annually.
- Unique Treatment Solution: Talicia is the only FDA-approved low-dose rifabutin-based therapy for H. pylori, addressing antibiotic resistance, and is recommended as a first-line treatment in the 2024 ACG Clinical Guidelines, which is expected to drive prescription growth significantly.
- Strategic Investment Support: Cumberland's $4 million investment in this initiative supports the marketing and operational efforts for Talicia, enhancing the collaboration between the two companies in the gastrointestinal disease sector and improving overall commercialization capabilities.
- Global Market Expansion: RedHill is actively exploring new market opportunities for Talicia in the UK and the Middle East, aiming to broaden market access and secure additional non-dilutive revenue streams, thereby increasing treatment accessibility for patients worldwide.
See More
RedHill Biopharma's RHB-102 Progress Drives 36% Rally, Stock Drops 4.29%
- Stock Volatility: RedHill Biopharma's stock fell 4.29% to $1.34 on Tuesday after a 36% rally on Monday, indicating potential profit-taking that may affect investor confidence in the short term.
- Development Progress: The company announced advancements for RHB-102 (Bekinda) in multiple gastrointestinal indications, utilizing the FDA's accelerated 505(b)(2) pathway, which aims to address GI side effects associated with GLP-1/GIP receptor agonist therapies, presenting significant market potential.
- Clinical Data Support: Clinical data for RHB-102 comes from the U.S. Phase 3 GUARD gastroenteritis study and the positive Phase 2 IBS-D study, both meeting their primary endpoints, which are expected to provide strong support for FDA approval and potentially reshape the GLP-1 market landscape.
- Market Impact: With up to 50% of patients discontinuing GLP-1 receptor agonists within three months due to side effects, successful development of RedHill's therapy could mitigate the projected $35 billion reduction in GLP-1 market valuations by 2030.
See More
